According to BriaCell Therapeutics latest financial reports the cash on hand of BCTX is $28.42M, an decrease of -48.22% to 2022. At the end of 2022 company had $54.89M cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $28.42M | -48.22% |
2022 | $54.89M | -28.33% |
2021 | $76.59M | 360332.37% |
2020 | $21.25K | -85.52% |
2019 | $146.71K | - |